Bayesian modeling of cost‐effectiveness studies with unmeasured confounding: a simulation study

Unmeasured confounding is a common problem in observational studies. Failing to account for unmeasured confounding can result in biased point estimators and poor performance of hypothesis tests and interval estimators. We provide examples of the impacts of unmeasured confounding on cost-effectiveness analyses using observational data along with a Bayesian approach to correct estimation. Assuming validation data are available, we propose a Bayesian approach to correct cost-effectiveness studies for unmeasured confounding. We consider the cases where both cost and effectiveness are assumed to have a normal distribution and when costs are gamma distributed and effectiveness is normally distributed. Simulation studies were conducted to determine the impact of ignoring the unmeasured confounder and to determine the size of the validation data required to obtain valid inferences.

[1]  Andrew Briggs,et al.  Statistical Analysis of Cost-Effectiveness Data , 2006 .

[2]  P. Garthwaite,et al.  A Bayesian approach to prospective binary outcome studies with misclassification in a binary risk factor , 2005, Statistics in medicine.

[3]  A O'Hagan,et al.  Bayesian cost‐effectiveness analysis from clinical trial data , 2001, Statistics in medicine.

[4]  Sander Greenland,et al.  Relaxation Penalties and Priors for Plausible Modeling of Nonidentified Bias Sources , 2009, 1001.2685.

[5]  Anirban Basu,et al.  Comparing alternative models: log vs Cox proportional hazard? , 2004, Health economics.

[6]  Paul Gustafson,et al.  Probabilistic Approaches to Better Quantifying the Results of Epidemiologic Studies , 2010, International journal of environmental research and public health.

[7]  R. Obenchain,et al.  Cost-Effectiveness Inferences from Bootstrap Quadrant Confidence Levels: Three Degrees of Dominance , 2005, Journal of biopharmaceutical statistics.

[8]  Richard Grieve,et al.  Bayesian Hierarchical Models for Cost-Effectiveness Analyses that Use Data from Cluster Randomized Trials , 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  Simon G Thompson,et al.  How Sensitive Are Cost-Effectiveness Analyses to Choice of Parametric Distributions? , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  Rolando De la Cruz.  Bayesian ideas and data analysis: An introduction for scientists and statisticians , 2012 .

[11]  Andrew R Willan,et al.  Cost-effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate. , 2008, Health economics.

[12]  Max O Bachmann,et al.  Cost Effectiveness and Resource Allocation Methods for Analyzing Cost Effectiveness Data from Cluster Randomized Trials , 2007 .

[13]  S. Schneeweiss.  Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.

[14]  P. Gustafson,et al.  Bayesian sensitivity analysis for unmeasured confounding in observational studies , 2007, Statistics in medicine.

[15]  Robert H Lyles,et al.  Validation Data-based Adjustments for Outcome Misclassification in Logistic Regression: An Illustration , 2011, Epidemiology.

[16]  Richard Grieve,et al.  Statistical methods for cost-effectiveness analyses that use observational data: a critical appraisal tool and review of current practice. , 2013, Health economics.

[17]  Hongwei Zhao,et al.  Average Cost-Effectiveness Ratio with Censored Data , 2012, Journal of biopharmaceutical statistics.

[18]  Sander Greenland,et al.  Modern Epidemiology 3rd edition , 1986 .

[19]  Lawrence C McCandless,et al.  A sensitivity analysis using information about measured confounders yielded improved uncertainty assessments for unmeasured confounding. , 2008, Journal of clinical epidemiology.

[20]  Jonathan A C Sterne,et al.  The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. , 2007, American journal of epidemiology.

[21]  A. Briggs,et al.  Statistical Analysis of Cost-effectiveness Data: Willan/Statistical Analysis of Cost-effectiveness Data , 2006 .

[22]  Sander Greenland,et al.  Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. , 2004, American journal of epidemiology.

[23]  Karen Price,et al.  Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetes. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  G. Baio,et al.  Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. , 2011, Atherosclerosis.